Exelixis (EXEL) Reports In-Line Q4 EPS, Slight Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Oppenheimer Upgrades Exelixis (EXEL) to Outperform
February 27, 2018 4:21 AM ESTOppenheimer upgraded Exelixis (NASDAQ: EXEL) from Perform to Outperform with a price target of $40.00.
Analyst Leah Rush Cann expects the company will continue to develop its commercial drugs Cabometyx & Cometriq as its partner Genetech continues to develop Cotellic. The analyst raises 2017-201 sales... More
